1.结核病真实世界数据研究 Real World Study of Tuberculosis；2.结核感染与其他呼吸道疾病 TB infection and other Pulmonary Diseases；3.抗结核新药筛选及研究 New anti-TB drugs Screening and Research
1．中华医学会结核病分会基础学组委员 Group Member of the Basic Research of the Tuberculosis Branch of Chinese Medical Association ；2.中国医促会结核病防治分会基础学组委员 Group Member of the Basic Research of Tuberculosis Control Branch of China International Exchange and Promotion Association for Medical and Healthcare
冯永红研究员近年来作为负责人承担、完成国家自然基金面上项目5项（30872364、81172806，81471563，81771692, 81971558）；在国际上，较早对凝血系统在结核病理发生中的作用进行了探索性研究（Chest 2018; J. Infect. Dis. 2014）。近年课题组主要基于结核病临床大数据研究，发现结核病发病的性别和年龄相关性（Front. Med.2019；Biol. Sex Diff.2018），迄今在国内外专业期刊发表研究性论文30余篇。
另外，自2007年起，作为主要负责人创建、并负责上海市抗结核药物筛选公共服务平台，累计为国内外进行结核病新药研究的企、事业单位和科研院所进行了数千次筛选评估，促进了国内抗结核原创新药研发。
Dr. Feng has undertaken and completed five projects supported by the National Natural Science Foundation of China (30872364, 81172806, 81471563, 81771692, 81971558). She is one of the researchers who firstly investigated the roles of platelets/coagulation factors in pathogenesis of tuberculosis（Chest 2018; J. Infect. Dis. 2014）. In recent years, her group mostly focused on the Big Data Study of Tuberculosis, with the interested topics including differential diagnosis of TB and association of the latent TB infection with other pulmonary diseases.
In addition, since 2007, as the founder and the person in charge, she has been responsible for the Shanghai Public Service Platform for anti-TB Drug Screening. Up to now, the platform has finished about 6,000 screenings for enterprises, institutions and research institutes conducting research on new drugs for tuberculosis, which promoted domestic research and development of innovative anti-tuberculosis drugs.
